Abstract
As previously reported, the activity of the large-conductance calcium (Ca2+)-activated potassium (K+) (BKCa) channel is strongly potentiated from the extracellular side of the cell membrane by certain benzofuroindole derivatives. Here, the mechanism of action of one of the most potent activators, 4-chloro-7-(trifluoromethyl)-10H-benzofuro[3,2-b]indole-1-carboxylic acid (CTBIC), is characterized. This compound, Compound 22 in the previous report (Chembiochem 6:1745–1748, 2005), potentiated the activity of the channel by shifting its conductance-voltage relationship toward the more negative direction. Cotreatment with CTBIC reduced the affinity of charybdotoxin, a peptide pore-blocker, whereas that of tetraethylammonium, a small pore-blocking quaternary ammonium, was not significantly altered. Guided by these results, scanning mutagenesis of the outer vestibule of the BKCa channel was launched to uncover the molecular determinants that affect CTBIC binding. Alanine substitution of several amino acid residues in the turret region and the S6 helix of the channel decreased potentiation by CTBIC. Homology modeling and molecular dynamics simulation showed that some of these residues formed a CTBIC binding pocket between two adjacent α-subunits in the outer vestibule of the channel. Thus, it can be envisioned that benzofuroindole derivatives stabilize the open conformation of the channel by binding to the residues clustered across the extracellular part of the subunit interface. The present results indicate that the interface between different α-subunits of the BKCa channel may play a critical role in the modulation of channel activity. Therefore, this interface represents a potential therapeutic target site for the regulation of K+ channels.
Footnotes
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported in part by the National Leading Research Laboratories [Grant 2011-0028665]; the Cell Dynamics Research Center [Grant 2011-0001154]; and Management of Climate Change Program [Grant 2010-0029084] from National Research Foundation funded by the Ministry of Education, Science and Technology of Korea.
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
ABBREVIATIONS:
- BKCa
- large-conductance Ca2+-activated K+
- TBIC
- 7-trifluoromethyl-10H-benzo[4,5]furo[3,2-b]indole-1-carboxylic acid
- CTBIC (LDD175)
- 4-chloro-7-(trifluoromethyl)-10H-benzofuro[3,2-b]indole-1-carboxylic acid
- 3D
- three-dimensional
- CTX
- charybdotoxin
- PCR
- polymerase chain reaction
- DPPC
- dipalmitoylphosphatidylcholine
- G/Gmax
- relative conductance
- G-V
- conductance-voltage relationship
- Slo1
- BKCa channel α-subunit
- TEA
- tetraethylammonium
- P-region
- pore region
- NS1619
- 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one
- BMS 204352
- 3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl).
- Received February 3, 2012.
- Accepted April 30, 2012.
- Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|